Background/Aims: Fabry disease (FD) is a rare inherited lysosomal storage disease with common and serious kidney complications. Enzyme replacement therapies (ERT) with agalsidase-α and -β were investigated to characterize their therapeutic effect on kidney function in FD patients with Classic phenotype. Methods: The prospective FD cohort consisted of 98 genetically confirmed patients (females, n = 61, males, n = 37). The median [interquartile range] follow-up time (time difference from first to last visit) was 9 [6, 12] years. The median age of ERT start was 36 [21 -54] years for females and 39 [28 -49] years for males. Results: A disease progression model was developed to (i) characterize the time course of estimated glomerular filtration rate (eGFR) and (ii) evaluate therapeutic effects of ERT on kidney function. Change in eGFR over time was best described by the linear model. Females had stable kidney function with and without ERT (eGFR slopes of -0.07 ml/min/1.73m^2 per year and 0.52 ml/ min/1.73m^2 per year, respectively). Males with ERT showed an eGFR decrease of -3.07 ml/ min/1.73m^2 per year. Conclusion: Mathematical disease progression modeling indicates that there is no clear therapeutic effect of ERT on kidney function in adult patients with Classic
Introduction
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (α-Gal A) resulting in a progressive intralysosomal accumulation of glycosphingolids in different cell types, plasma and urine [1, 2] . In a majority of patients, initial signs and symptoms related to FD appear in childhood and include acroparaesthesia, angiokeratoma, abdominal pain, hypohidrosis and corneal dystrophy. Inflammation and fibrosis associated with disease progression leads to kidney and heart failure, cerebrovascular disease and early mortality [1] . Deposition of undergraded glycosphingolipid substrate occur in all kidney cells and structures including podocytes, mesangial, tubular, interstitial and vascular endothelial cells [3] . Fabry nephropathy is linked to cardiovascular morbidity and mortality in FD patients [4] . Although males have more severe Fabry disease than females, heterozygous females with X-chromosomal inactivation can also be severely affected depending on random X-chromosomal inactivation [5] . "Classic" and "Later-Onset" phenotypes are the two major FD subtypes. Affected males with the Later-Onset phenotype have residual α-Gal A activity, later-onset cardiac and/or renal disease, and lack the major early-onset classical manifestations, including angiokeratoma, acroparesthesias, hypohidrosis, and the ocular abnormalities [6] [7] [8] [9] .
Enzyme replacement therapy (ERT) with recombinant α-Gal A was approved in Europe in 2001. There are two preparations available on the market: agalsidase-α with the licensed dose of 0.2 mg/kg or agasidase-β dosed at 1 mg/kg body weight, each administered every 2 weeks intravenously. ERT initiation is recommended in classically affected males and females as soon as early clinical signs of FD occur [10] . Studies have shown a kidney tissue clearance of glycosphingolipid accumulation as a result of ERT [11] , long-term ERT stabilized and preserved kidney function in some FD patients [12] [13] [14] . Recent studies suggest that FD patients with chronic kidney disease (CKD) stage 3 or 4 may not benefit from ERT as clinically meaningful events continue to occur in these patients despite treatment [15] . Proteinuria seems to be associated with decreased effectiveness of ERT [16, 17] .
To further enhance treatment strategies for FD patients, key determinants of variability in kidney disease progression in FD patients with and without ERT need to be identified and characterized. For this reason a longitudinal, mathematical model was developed [18] to (i) account for individual behavior of female and male FD patients, (ii) characterize individual model parameters and the inter-individual variability, (iii) identify and quantify effects of covariates on kidney disease progression, measured as change in kidney function (eGFR) over time. In order to analyze a homogeneous group, the performed disease progression analysis focused on patients with the Classic phenotype of FD.
Subjects and Methods
This is a retrospective analysis of a prospective, multi-center cohort in Switzerland. The study was conducted in accordance with the principles of Helsinki Declaration. Patients who were alive were contacted, and signed a written informed consent.
Study population and clinical data
The prospective FD cohort consisted of 98 genetically confirmed patients (females, n = 61, males, n = 37). The cohort was established in 2001 when ERT was approved and offered to FD patients. Consecutive FD patients were registered and monitored at two tertiary care hospitals -University Hospitals Zürich (90 patients) and Bern (8 patients) Switzerland. Patients on renal replacement therapy (RRT) -kidney transplantation or dialysis (n = 5 all male) -at baseline and patients with the Later-Onset phenotype (n=9) were excluded from the analysis.
The analysis included all available renal data extracted from the FD patients` medical records until kidney transplantation (n = 5), death (n=10) or March 2015. Kidney function, expressed as eGFR according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [19] , and proteinuria, expressed as protein/creatinine or albumin/creatinine ratio, were analyzed. Information on concomitant angiotensinconverting enzyme (ACE)-inhibitors and angiotensin-receptor blockers (ARB) therapy was also recorded and analyzed as covariates. Kidney biopsies were performed in 11 patients, 6 males and 5 females, all the biopsies confirmed the Fabry nephropathy.
Treatment
ERT was initiated according to the written local guidelines. Accordingly, ERT was indicated in all males, independent from age, phenotype and symptoms. In females, ERT was indicated if they had proteinuria of more than 300 mg per day, Fabry-typical kidney biopsy findings, signs of Fabry cardiopathy such as left ventricular hypertrophy or arrhythmia, stroke or transient ischemic attack (TIA), persistent FD-related neuropathic pains despite conventional analgetic therapy, and or gastrointestinal symptoms.
In all patients, ERT was prescribed at the licensed dose of either 0.2 mg/kg body weight of recombinant agalsidase-a (Replagal) or 1 mg/kg body weight agalsidase-b (Fabrazyme) and given intravenously every 14 days. We retrospectively calculated the actual, administered ERT amount per kg by multiplying the dose contained in a vial by the number of vials and divided this amount by the current body weight documented in the medical records at each visit. We separately computed cumulative doses for Replagal and Fabrazyme in patients who switched ERT. Cumulative doses were calculated according to the respective preparation of Replagal and Fabrazyme.
Phenotyping
Phenotyping was based on GLA mutation type: frame-shift, nonsense, consensus splice-site mutations, large insertions and deletions, and some missense mutations, which result in no or <2% of mean normal enzymatic activity were classified as having the Classic phenotype. In contrast, some missense and some alternative splicing mutations result in enzymes with residual enzymatic activity and the Later-Onset phenotype. To determine, if the missense mutations caused the Classic or Later-Onset phenotype, clinical data, substrate levels, and in vitro expression assays were evaluated to determine the mutation's phenotype [6, 20, 21] .
Assessment of kidney function
As measure of kidney function, the eGFR was derived from serum creatinine scr (mg/dL) and age (years) by the Chronic Kidney Disease Epidemiology Collaboration [19] .
Characterizing relationship between age and kidney function at baseline
In a first step, the relation between age at baseline (Age Base ) and eGFR at baseline (eGFR Base ) was investigated by linear regression (1) where a is the intercept and m the slope. Female (54 subjects) and male (25 subjects) were separately investigated.
Developing disease progression model to describe change in kidney function over time
In the second step, a disease progression model [22, 23] To describe eGFR change eGFR(t) over time t (months), the linear model (2) where eGFR Base is the initial intercept at t=0 and eGFR Slope the slope, was most appropriate to describe available data. Also other disease progression models such as exponential decay or oscillating approaches were tested. However, estimated parameters for these models always produced a linear prediction, confirming our chosen linear model Eq. (2).
Incorporating of patient characteristics and covariate effects on kidney function in model
FD patients with more than one creatinine measurement were included into the dynamical analysis (n = 67). Non-linear mixed effect modeling [18, 24] was applied to estimate the typical (also called mean or population) parameters and individual parameters. A normal distribution for the individual eGFR slopes eGFR Slope,i was assumed to allow negative values for 1 < i < n where n is the number of individuals. Individual eGFR baselines eGFR Base,i were described best by a log-normal distribution. The variance of these parameter distributions is denoted by w Ɵ k with 1 < k < n parm , where n parm = 2 is the number of model parameters. Categorical covariates Cov Cat , such as gender, were implemented at the individual model parameters Ɵ i,k with (3) In Eq. (3) 
Kindey disease progression model according to baseline albuminuria
Patients were categorized into three groups of albuminuria according to the recent KDIGO definitions [25] : A1 with albuminuria < 3 mg/mmol, A2 3-30 mg/mmol, A3 > 30 mg/mmol. Computed individual slopes from the longitudinal analysis of treated FD patients were grouped into these three albuminuria categories. Albuminuria at baseline was defined as the first available measurement in each study patient.
Analysis of serum-mediated ERT inhibition
Between January 2014 and December 2016, blood for biobanking was drawn, blood samples were centrifuged and serum was immediately frozen at −80°C. ERT inhibition assays were performed as reported elsewhere [26] [27] [28] in 15 males and 20 females who were included into the dynamical analysis. The measurements have been performed as triplicates. Since ERT-inhibition develops within the first weeks after ERT treatment [26] and seems to be irreversible, serum samples from recent visits are most likely useful to reflect the inhibition status over the treatment period. Patients with a mean ERT inhibition >50% were designated as ERT inhibition positive according to recent literature [27] .
Statistical-mathematical analyses
Categorical variables were expressed as proportions, continuous variables as medians with interquartile ranges [IQR] . All statistical tests were two-sided, and p values <0.05 were considered significant.
The dynamical analysis was performed with the non-linear mixed effect software package Monolix 4.3 [29] . The other analyses were performed using statistical software package R [30] .
Results

Follow-up and treatment
The average number of visits was 5 per patient and the overall number of visits was to agalsidase-a (due to shortage of agalsidase-b), two patients from agalsidase-a to agalsidase-b (due to patient`s priority) and two from agalsidase-a to agalsidase-b and back to agalsidase-a (due to logistic reasons).
This FD cohort was analyzed to characterize the effects of ERT on the renal disease and progress following ERT. First, the relationship of age and eGFR calculated according to Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) [19] at initiation of ERT was investigated in Classical patients not on RRT. Second, a longitudinal analysis with a disease progression model was performed in patients with two or more visits. Only one male was untreated and therefore excluded from the analysis. Baseline characteristics of included patients (n =67) are summarized in Table 1 . The Flow-chart is shown as Figure 1 . 437 . The median follow-up time of all included patients (time difference from first to last visit) was 9 [6 -12] years. A total of 53 FD patients were on ERT for at least 8 [6 -11] Females were started on ERT at 36 [21 -54] years, males at 39 [28 -49] years of age. Among treated females, the primary cause of ERT initiation was acroparesthesia (n=8), cardiomypathy (n=7), stroke (n=3), renal involvement diagnosed by biopsy (n=1), cardiomypathy and renal involvement (n=2).
Overall, 39 patients received agalsidase-a and four agalsidase-b throughout the observational period. Six patients were switched from agalsidase-b 
Relationship between age and kidney f u n c t i o n : baseline data
The relationship of age and eGFR at initiation of ERT was investigated with Eq. (1), i.e. age at baseline vs. eGFR at baseline. Baseline data from female FD patients (n=54) showed a linear relationship with a significant (p<0.01) negative slope and a reasonable coefficient of determination (R^2 = 0.57). Notably, only 7% of female FD patients (n = 4) were staged in CKD 3 (< 60 ml/ Table 2 . Baseline characteristics of treated and untreated patients with the Classic phenotype of Fabry disease patients included in disease progression model min/m1.73m^2) at first visit. The age of these four females was 60 years or higher. Baseline data from male FD patients (n=25) also had a significant (p<0.01) negative slope, although with a lower coefficient of determination (R^2<0.29). In contrast to female FD patients, 24% of the male FD patients (n=6) were staged in CKD 3 or 4 at first visit. The ages of these six males ranged from 22 to 52 years. One of these six patients showed an eGFR value below 30 ml/min/1.73m^2 (CKD stage 4) . Hence, approximately one-fourth of the male FD patients in the investigated cohort had an already significant renal impairment prior to initiation of ERT. In Figure 2 , the results for female (panel A) and male (panel B) subjects are shown. Estimates of model parameters and their variability are summarized in Table 1 .
Change in kidney function and covariate effects: longitudinal data FD patients with more than one creatinine measurement were considered (n = 67). Baseline characteristics of treated and untreated FD patients are presented in Table 2 , the genotype information in Table 3 . Among females, 22 were 'untreated' (total number of measurements = 82). To account for the relationship between age and eGFR at initiation of ERT, i.e., age at baseline was a significant covariate on eGFR Base (p<0.05), this covariate effect was included in all consecutive disease progression models. After accounting for this age effect on eGFR at baseline, values of mean arterial pressure (MAP), body weight (WT) and body mass index (BMI) at baseline had no influence on eGFR Base and age at baseline showed no effect on the eGFR Slope . Furthermore, time varying covariates WT, BMI and MAP did not influence the eGFR Slope . Estimates of covariate effects are provided in Table 4. A total of 45 'treated' FD patients (females, n = 21, males, n = 24) with a total of 317 Table 4 . Female FD patients without ERT had a slight decrease in eGFR (eGFR Slope = -0.006 ml/min/1.73m^2/month) ( Figure 3A) , whereas 'treated' females showed a marginal increase of eGFR over time (eGFR Slope = 0.0428 ml/min/1.73m^2/month) ( Figure 3B) . Difference of the eGFR slopes between 'untreated' females and those with ERT was not statistically significant. Further magnitude of ERT effect on eGFR slope was marginal in females with stable, almost unchanged kidney function over time. In contrast, males with ERT had a noticeable decrease of eGFR over time (eGFR Slope = -0.256 ml/min/1.73m^2/ month), which was significantly different from that observed in females on ERT (p<0.01) ( Figure 3C ).
There was no difference in effects of agalsidase-α and -β on eGFR slopes. However, the number of patients on agalsidase-β was small. The actual administered ERT dose had no clear effect on eGFR slope. In patients with eGFR at baseline below and above 60 ml/ min/1.73m^2, the eGFR slopes were similar. In addition, a covariate test of eGFR at baseline directly at the slope showed no significant effect.
Analysis of albuminuria and proteinuria
Protein/creatinine ratios in the urine were available from 46 patients with a total of 174 measurements and albumin/creatinine ratios from 51 patients with a total of 217 measurements. No covariate effects on the slope of these ratios over time were found, especially no ERT dependent difference. At baseline, the urine albumin/creatinine and protein/creatinine ratios were significantly higher in males than in females. However, since longitudinal albuminuria and proteinuria data were associated with a high variability, no disease 
Relationship of eGFR slope and albuminuria at baseline
Kidney function decrease over time, characterized by eGFR slopes, was significantly (p < 0.05) less severe in the first (albuminuria at baseline < 3 mg/mmol; median slope = 0.019) and second (3 -30 mg/mmol, median slope = 0.014) group as compared to the the third (> 30 mg/mmol; median slope = -0.371) category (Figure 4) . 
Relation of eGFR slope and serum-mediated ERT inhibition
Three of 15 treated males showed a significant inhibition of >50%: first male currently 52 years old, ERT start with 38 years of age, second male currently 57 years old, ERT start with 44 years of age, third male currently 51 years old, ERT start with 39 years of age. Their eGFR slopes were not significantly different to the non-inhibiting male population (data not shown).
No female showed a significant serum-mediated ERT inhibition in this cohort.
Clinical events
Overall, 27 events occurred in 18 of 67 Classical patients who were included into the dynamic analysis. Among treated females, 1 suffered a new-onset AF, 5 strokes, 1 needed a pacemaker and 2 died (reason unknown). No events occurred among untreated females. Among treated males, 3 patients received a kidney transplantation, 4 suffered a new-onset aerial fibrillation (AF), 4 strokes, 1 myocardial infarction, 2 needed a pacemaker and 3 died (1 due to sepsis, 2 unknown) ( Table 2 ). One of the males with the mutation c.902G>A was 51 years old when he was diagnosed and started on ERT with an advanced kidney failure (eGFR of 15 ml/min/1.73m^2). The other male with the same mutation was 36 years old when he was diagnosed and started on ERT with a normal eGFR and proteinuria of 0.6 g/24 hours. The male with the mutation c.1196G>C was 42 years old when he was diagnosed with proteinuria of 1.8 g/24 hours and eGFR of 62 ml/min/1.73m^2. He unfortunately rejected ERT. The other two males with c.352C>T and c.644A>G were 74 and 36 years old respectively, and had a normal kidney function without proteinuria, both received ERT.
Later-Onset phenotype patients
Four females with the mutations, c.902G>A (p.Arg301Gln) (two related females), c.416A>G (p.Asn139Ser), c.337T>C (p.Phe113Leu) had a Later-Onset phenotype.
One of the both females with the mutation c.902G>A (mother) was 61 years old when diagnosed and started on ERT with an eGFR of 88 ml/min/1.73m^2 and proteinuria of 0.8 g/24 hours. Her 25-year-old daughter, had a normal kidney function without proteinuria and needed no ERT. Also the 40-year-old female with the mutation c.416A>G and the 33-year-old with c.337T>C had normal kidney function and needed no ERT.
This group did not form a basis for comparison due to its small sample size and heterogeneity and was therefore excluded from the analysis.
Discussion
This analysis of a large well documented genetically proven homogeneous group of Classic FD phenotype patients with and without ERT investigated longitudinal eGFR data over a long follow-up period. To account for both, individual and population level disease progression, non-linear mixed effect modelling (NLME) was applied. Although NLME is frequently applied in clinical drug development, to our knowledge, it is the first time that this method was utilized to characterize progression of the Fabry nephropathy over time, quantify effects of ERT, as well as key covariates on kidney function. Previous studies used linear multivariate regression models for outcome analyses as a common statistical tool [16, 31, 32] .
The developed model included the relationship of age at baseline on eGFR at baseline. The finding that kidney function decreases with age is a known fact for the normal population [33] as well as patients with FD [1, 2] . Agalsidase-a and agalsidase-β had a dose-independent effects on the development of kidney function in this cohort. Additionally, covariates such as mean arterial pressure, BMI, treatment with ACE-inhibitors and ARB had no influence on the eGFR slope and proteinuria. By modeling, kidney function remained stable in female FD patients without ERT (eGFR slope -0.07 ml/min/1.73m^2 per year) and those with ERT (0.52 ml/min/1.73m^2 per year) without a significant difference between these two slopes. In contrast, male FD patients showed a clear decline of kidney function over time despite ERT (eGFR slope -3.07 ml/min/1.73m^2 per year), which appears to be faster than that observed in normal population [33] . According to the developed model, male FD patients can pass through several CKD stages ending up with end-stage renal disease within 15 years after initiation of ERT later in the disease.
Importantly, the majority of symptomatic female patients received ERT because of neurological and cardiovascular symptoms and events. In 3 of 21 treated female patients, ERT was initiated due to FD-related nephropathy. The baseline protein excretion and need of ACE-inhibitors therapy seems to be higher in the treated than in the untreated female group (Table 2) . Therefore, the treated female patients might have had a more pronounced kidney involvement at baseline than those without ERT (Table 2) . Thus, enzyme replacement therapy could have stabilized the kidney function in these females.
In contrast, ERT showed no clear treatment-related benefit on the development of Fabry nephropathy in male patients in this cohort. One of the possible reasons for the latter observation could be that the initiation of ERT was relatively late, i.e. after 35 years of age. This is an "old" FD population where a great proportion of the patients had advanced kidney disease, when ERT was initiated and offered to all FD patients in 2001. Additionally, as FD is rare, patients experience a delayed diagnosis also resulting in treatment delay [34] . In agreement with our results, a significant loss of renal function over time has repeatedly been demonstrated in patients with FD even under ERT. In an analysis of Fabry Outcome Survey, Beck and co-authors demonstrated for example that the renal disease progression under ERT is more accelerated in patients with already impaired kidney function at baseline [31] . These findings support the assumption that early therapy initiation benefit kidney function.
Of note, the eGFR slopes of the three males with an endogenous serum-mediated inhibition of the recombinant enzyme were not significantly different to the non-inhibiting male population. A possible explanation of this finding is that in this cohort with late ERT initiation, the ERT effects were limited due to the advanced disease stage at baseline in both -inhibiting and non-inhibiting -groups. This finding is in agreement with the main study results. However, these studies are limited since the sample size of inhibiting males is small. Importantly, no female showed a significant serum-mediated ERT inhibition in this cohort, also as shown by Linthorst et al, Rombach et al and Lenders et al [26] [27] [28] . This is the first study to show that obviously, classical females do not develop a serum-mediated ERT inhibition even after many years of ERT.
Early FD diagnosis could prevent kidney disease progression through the timely initiation of treatment. As shown in our results, the disease progression was accelerated if ERT patients already had a more severe albuminuria at baseline. Studies suggest that maximal treatment effect in Fabry nephropathy can be achieved at an early stage with normal or almost normal kidney function [11, 35, 36] . Tondel et al have described beneficial effects of ERT detected in kidney biopsies regarding clearance of glomerular endothelial and mesangial cell inclusions in patients with well-preserved renal function [11, 35] . A recent study by Germain and colleagues showed that less affected individuals with a better preserved kidney function at baseline benefited from ERT, experiencing better renal and cardiovascular outcomes during the observational period [36] . Moreover, in male FD patients, enhanced therapeutic outcomes may occur if we increase the ERT dose [35, 37, 38] , or frequency of infusions [39] , in combination with intensified additional medication such as ARBs and ACE inhibitors [16] . In patients with amenable mutations, pharmacological chaperones have been shown as a useful therapeutic alternative [40, 41] . Their combination with ERT could further increase therapeutic effects [42] , this assumption needs to be confirmed in clinical studies. Furthermore, enhanced uptake of α-gal A into target cells [43] and substrate reduction therapy [44] have been tested in mouse model experiments and can possibly be implemented in human studies in the future, especially in combination with ERT.
It can't be excluded that our male FD patients had experienced treatment benefit despite their deterioration of kidney function. Studies demonstrated a long-term renal stabilization following ERT in FD patients [12, 14, 45, 46] . However, placebo-controlled clinical trials in Fabry nephropathy are scarce and the choice of an appropriate control group in the assessment of the treatment response especially in males remains crucial.
Several limitations merit consideration. First, we included only renal parameters of adolescent and adult FD patients into the longitudinal mathematical model. The time course of eGFR could be non-linear in children with FD. Therefore, further investigations with longitudinal models including pediatric and adult FD patients are warranted. Such expanded model might allow evaluating effects of timely ERT initiation in pediatric males with classical phenotype. Second, we did not test a larger variation of ERT dose on Fabry nephropathy development as the really applied ERT dose did not greatly vary in this cohort. We therefore cannot exclude a possible dose-dependent beneficial effect on Fabry nephropathy. Third, we did not systematically conduct renal biopsies in our patients, also LysoGb3 measurements over time were not available in this "old" FD population. However, follow-up kidney biopsies and LysoGb3 in FD patients could assess treatment response, exclude renal pathologies beyond Fabry nephropathy and confirm diagnosis in uncertain cases [47] [48] [49] . Fourth, mathematical disease progression modeling should ideally contain histological findings based on scoring system for renal pathology in Fabry nephropathy [50] . Moreover, early renal tissue biomarkers need to be added to the pharmacometric modeling approaches to develop prognostic markers for pediatric FD patients.
The strength of the study is that we analyzed a large well documented genetically proven homogeneous group including only patients with the Classic phenotype of FD.
Conclusion
No clear therapeutic effect of enzyme replacement therapy on kidney function in adult patients with Fabry disease was found, presumably because ERT was initiated late in the disease. Interpretation of these findings should take into account that the study is not randomized and lacks a placebo controlled group.
In a future project, mathematical disease progression modeling will be applied to characterize ERT effects on kidney function in pediatric FD patients. Further investigations are warranted to clarify whether earlier ERT initiation, higher ERT dose or more intensive therapies can preserve kidney function, especially in pediatric and adult male FD patients. Mathematical disease progression modeling can add substantial knowledge in the assessment of the therapeutic effects of ERT in female and male FD patients.
